Showing 4931-4940 of 5646 results for "".
- World Leaders Pledge $8 Billion To Fight COVID-19; US Skips Meetinghttps://modernod.com/news/world-leaders-pledge-8-billion-to-fight-covid-19-us-skips-meeting/2477711/A global alliance responded to calls to fight the coronavirus pandemic on Monday, as world leaders pledged some $8 billion to develop vaccines and treatments to fight COVID-19, according to an NPR
- Adverum Biotechnologies Reports Positive Interim Data of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-reports-positive-interim-data-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477705/Adverum Biotechnologies announced new interim clinical data from Cohorts 1-3 of the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD) and provided
- Alnylam, Vir to Advance Experimental RNAi Therapeutic VIR-2703 as Potential COVID-19 Treatmenthttps://modernod.com/news/alnylam-vir-to-advance-experimental-rnai-therapeutic-vir-2703-as-potential-covid-19-treatment/2477702/Alnylam Pharmaceuticals and Vir Biotechnology announced that they plan to develop VIR-2703, an investigational RNAi therapeutic targeting the SARS-CoV-2 genome as an inhalational formulation for the potential treatment or prevention of COVID-19. “To our knowledge, this is one of the
- AAO Surveys Reveal Severe Effect COVID-19 Is Having on Ophthalmology Practiceshttps://modernod.com/news/american-academy-of-ophthalmology-releases-covid-19-survey/2477701/The American Academy of Ophthalmology (AAO) released the initial findings of a series of COVID-19 pulse surveys, which aim to reveal the pandemic’s effect on ophthalmology practices and their patients. The pulse surveys will be used to advocate for additional relief and to develop resources to he
- NIH Mobilizes National Innovation Initiative For COVID-19 Diagnosticshttps://modernod.com/news/nih-mobilizes-national-innovation-initiative-for-covid-19-diagnostics/2477698/The National Institutes of Health (NIH) announced a new initiative aimed at speeding innovation, development, and commercialization of COVID-19 testing technologies. With a $1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx) in
- An Imaging Method To Help Us See Behind Our Eyeshttps://modernod.com/news/an-imaging-method-to-help-us-see-behind-our-eyes/2477684/The choroidal and retrobulbar blood vessels sit at the deep region of our eyes, supplying oxygen and nutrients to the retina. They are vital to our vision and the health and structure of our eyes. However, we don’t understand these important blood vessels as well as we should, because current ima
- Widely Used Surgical Masks Are Putting Health Care Workers At Serious Riskhttps://modernod.com/news/widely-used-surgical-masks-are-putting-health-care-workers-at-serious-risk/2477666/With medical supplies in high demand, federal authorities say health workers can wear surgical masks for protection while treating COVID-19 patients—but growing evidence suggests the practice is putting workers in jeopardy, according to a
- Congress Urges FDA to Better Police, Evaluate COVID-19 Antibody Testshttps://modernod.com/news/congress-urges-fda-to-better-police-evaluate-covid-19-antibody-tests/2477665/Members of Congress have called on the FDA to re-evaluate its stance toward COVID-19 antibody tests. Since mid-March, the agency has allowed diagnostic developers to bring their products to market without any outside evaluation that the results they produce are accurate, according to a
- Clearside Biomedical Revises NDA Resubmission Timeline and Xipere Commercial Partnership with Bausch Healthhttps://modernod.com/news/clearside-biomedical-revises-nda-resubmission-timeline-and-xipere-commercial-partnership-with-bausch-health/2477660/Clearside Biomedical announced an update to the Xipere (triamcinolone acetonide suprachoroidal injectable suspension) new drug application (NDA) resubmission timeline and to its commercialization and development partnership with Bausch Health Companies and Bausch + Lomb.
- Sanofi/Regeneron and Roche Report Mixed Results for Potential COVID-19 Treatmentshttps://modernod.com/news/sanofi-regeneron-and-roche-report-mixed-results-for-potential-covid-19-treatments/2477661/Sanofi and Regeneron Pharmaceuticals said that preliminary results from the phase 2 portion of an ongoing study showed that the IL-6 receptor antibody Kevzara (sarilumab) had “no notable benefit” on clinical outcomes v